GBI has unveiled SOURCE, a comprehensive market tool for tracking the Chinese biotechnology and pharmaceutical sectors – the first of its kind in China. SOURCE covers the breadth of the Chinese biopharma industry, providing users with a unique view into the competitive landscape and ever-evolving regulatory climate, while simultaneously arming subscribers with an unmatched well of data to inform and guide strategic decisions. Recent explosive growth in China’s biopharma market – which shows no sign of slowing – makes SOURCE a crucial tool in understanding China’s increasingly complex and competitive market.

The scope of coverage found in SOURCE is unprecedented in scale and unmatched by anything else currently on the market. SOURCE offers high-level overviews of national and regional conditions, in addition to drilled-down detailed information on all marketed products, registered manufacturers, pipeline candidates, registered companies and market access data (tendering, pricing, reimbursement and Essential Drug List status).

In addition to SOURCE’s data-driven offerings, GBI has also launched SOURCE News, a daily newswire covering the most important stories in the Chinese healthcare industry, from breaking policy announcements to major company mergers, regional pilot programs and product approvals. This service, which is included in every SOURCE subscription, is also available as a stand-alone product called SOURCE Select.